Menu
Search
|

Menu

Close
X

KemPharm Inc KMPH.OQ (NASDAQ Stock Exchange Global Market)

2.51 USD
-0.04 (-1.57%)
As of 5:40 PM BST
chart
Previous Close 2.55
Open 2.57
Volume 17,215
3m Avg Volume 35,346
Today’s High 2.58
Today’s Low 2.51
52 Week High 8.35
52 Week Low 2.46
Shares Outstanding (mil) 14.66
Market Capitalization (mil) 55.33
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-2.425
FY17
-2.961
FY16
-1.164
FY15
-6.456
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
--
5.74
Price to Book (MRQ)
vs sector
--
5.00
Price to Cash Flow (TTM)
vs sector
--
23.28
Total Debt to Equity (MRQ)
vs sector
--
16.89
LT Debt to Equity (MRQ)
vs sector
--
12.55
Return on Investment (TTM)
vs sector
-57.85
14.60
Return on Equity (TTM)
vs sector
--
16.33

EXECUTIVE LEADERSHIP

Travis Mickle
Chairman of the Board, President, Chief Executive Officer, Since 2014
Salary: --
Bonus: --
Timothy Sangiovanni
Principal Accounting Officer, Vice President, Corporate Controller, Since 2017
Salary: --
Bonus: --
Gordon Johnson
Chief Business Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2500 Crosspark Rd Ste E126
CORALVILLE   IA   52241-4710

Phone: +1319.6652575

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

SPONSORED STORIES